Video Shorts

Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

Expert Insight on FDA Approval of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

The Evaluation of CELMoDs in Multiple Myeloma

Highlighting the Potential Implications of the Ongoing INAVO123 Trial in HR+ Breast Cancer

STELLAR-303 Paves the Way for Potential FDA Approval of Immunotherapy-Based Regimen in MSS CRC

Deconstructing Clinical Trial Interpretation for Fellows

Starving Breast Cancer of Copper to Stop Disease From Spreading

Highlighting the Role of Pathologists in Breast Cancer Care

The Importance of Patient Selection for Breast Cancer Treatment Optimization

Boosting Gender Equity in the Oncology Workforce

Tracing the Evolution of Multidisciplinary Cancer Care

Go Behind-the-Scenes With OncLive at TCT 2026

Reducing Time to Breast Cancer Screening and Diagnosis

Exploring the Significance of a Pembrolizumab-Based Regimen in Ovarian Cancer

Targeting ENPP3 in RCC

Prostate Cancer Topics to Watch at ASCO GU 2026

Bladder Cancer Abstracts to Watch at ASCO GU 2026

Zanzalintinib Plus Atezolizumab Is One Step Closer to FDA Approval in Previously Treated mCRC

Kidney Cancer Abstracts to Watch at ASCO GU 2026

FDA Draft Guidance on MRD End Points in Myeloma Trials

Overused Buzzwords in Hematology and Oncology

Tackling Lifileucel in Metastatic Melanoma and Other Topics at TCT 2026

Hematologic Oncologists Share Conference Must-Haves

Zanidatamab-Based Regimens Could Be A ‘Game Changer’ for First-Line HER2+ GEA Paradigm

TCT 2026: CAR T-Cell Therapy Expert Insights

International Chondrosarcoma Awareness Day: Targeted Therapies Gain Ground in Rare Bone Cancer

Previewing Loncastuximab Tesirine in Heavily Pretreated Patients With Diffuse Large B-Cell Lymphoma

Prophylactic Dexamethasone Mitigating Neurotoxicity in Multiple Myeloma

The Role of Molecular and Genetic Testing in Ph+ Acute Lymphoblastic Leukemia

5-Year Data Update from the Phase 2 ELARA Trial